dupilumab
regeneron,sanofi
['dupixent', 'dupilumab']
$ dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 
This is an automated account sharing new press releases in real time from https://t.co/7iCFuj68H6